Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Siemens' DPC (Diagnostic Products Corporation) buy gets German OK:

This article was originally published in Clinica

Executive Summary

Siemens' proposed acquisition of Los Angeles, California-based immunodiagnostics company Diagnostic Products Corporation (DPC) has received clearance from German antitrust authorities. The news comes shy of a week after the US Federal Trade Commission gave the go-ahead to the $1.86bn transaction (see Clinica No 1211, p 14). The companies still require shareholder approval before closing the acquisition.

You may also be interested in...



Source: 3 Former Obama US CMS Officials Being Considered To Lead Biden’s Medicare Agency

The three names under consideration also have a history of focusing on helping underprivileged communities get access to health care.

Hikma Opens Discussions To Acquire GSK OTC, Rx Businesses In Egypt, Tunisia

With operations in the MENA region already tracking to $700m in revenues for 2020, Hikma is looking to grow the business further after beginning negotiations with GSK to buy certain of the originator’s businesses in Egypt and Tunisia.

Pfizer's Xeljanz Post-Marketing Study Raises Safety Alarms

A safety study of Pfizer's anchor immunology brand Xeljanz showed higher rates of heart attacks and cancer versus a TNF inhibitor.

Topics

UsernamePublicRestriction

Register

OM005224

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel